News
Displaying 51–60 of 538
-
Atsena to Launch Part B of Phase 1/2 Clinical Trial for XLRS Gene Therapy
Research NewsThe Foundation is a founding investor in Atsena.
-
Research News
The company is also planning to conduct the clinical trial at sites in the EU.
-
Research News
The company has also launched a natural history study of patients to inform the planned clinical trial.
-
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Research NewsKnown as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
Foundation News
ARPA-H award establishes multi-disciplinary consortium of industry experts to address current limitations and advance innovative technologies for vision-restoring whole eye transplantation.
Goal to bring light to those who are blind through first-ever successful vision recovery in six whole eye transplants in humans by 2030.
-
Research News
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
Research NewsThe Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
